Benitec Biopharma Limited (NASDAQ:BNTC) Receives $23.83 Average PT from Analysts

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has been given an average recommendation of "Buy" by the nine brokerages that are covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $23.83.

Several analysts have recently commented on BNTC shares. HC Wainwright reaffirmed a "buy" rating and set a $28.00 price objective on shares of Benitec Biopharma in a research report on Monday, May 19th. JMP Securities reaffirmed a "market outperform" rating and set a $20.00 price objective on shares of Benitec Biopharma in a research report on Thursday, May 15th.

Institutional Trading of Benitec Biopharma

Hedge funds have recently bought and sold shares of the business. Ameriprise Financial Inc. grew its position in Benitec Biopharma by 138.4% in the 4th quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company's stock valued at $448,000 after purchasing an additional 20,597 shares during the period. 683 Capital Management LLC acquired a new stake in Benitec Biopharma in the 4th quarter valued at $452,000. Northern Trust Corp grew its position in Benitec Biopharma by 54.2% in the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock valued at $482,000 after purchasing an additional 13,425 shares during the period. Informed Momentum Co LLC acquired a new stake in Benitec Biopharma in the 1st quarter valued at $512,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Benitec Biopharma in the 1st quarter valued at $597,000. Institutional investors and hedge funds own 52.19% of the company's stock.

Benitec Biopharma Trading Down 6.2%

NASDAQ:BNTC traded down $0.81 on Monday, reaching $12.35. 199,226 shares of the stock traded hands, compared to its average volume of 45,937. The firm has a market capitalization of $324.19 million, a price-to-earnings ratio of -8.18 and a beta of 0.44. The company's 50 day moving average is $14.44 and its 200-day moving average is $12.92. The company has a current ratio of 14.80, a quick ratio of 14.80 and a debt-to-equity ratio of 0.01. Benitec Biopharma has a 1-year low of $6.66 and a 1-year high of $17.15.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.12. Equities research analysts anticipate that Benitec Biopharma will post -1.48 EPS for the current fiscal year.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.